[Based on Japanese GAAP]
Operating Results
Overview of Operating Results
-
Net sales
17,384 million yen
YOY (1.5)%
-
Operating profit
711 million yen
YOY (51.4)%
-
Ordinary profit
817 million yen
YOY (48.7)%
-
Profit attributable to owners of parent
533 million yen
YOY (57.5)%
-
Earnings per share
18.78 yen
YOY (57.6)%
During the first quarter of the current consolidated fiscal year, the domestic economy showed a gradual recovery trend, supported by improvements in employment and income conditions. However, the situation remains uncertain due to continued price increases, developments in U.S. trade policy, and geopolitical risks such as the situation in the Middle East. The Group's core pharmaceutical business continues to face a challenging business environment due to ongoing drug price revisions, rising manufacturing costs, and other factors. Under these business conditions, net sales decreased by ¥257 million YoY to ¥17,384 million (down 1.5% YoY). In terms of profitability, due to increases in cost of sales, research and development expenses, and other factors, operating profit was ¥711 million (down 51.4% YoY), ordinary profit was ¥817 million (down 48.7% YoY), and quarterly profit attributable to owners of parent was ¥533 million (down 57.5% YoY).
Segment
Net sales
(Millions of yen)
| Segment name | 1Q | 2Q | 3Q | Full year |
|---|---|---|---|---|
| Pharmaceutical business | 14,484 | |||
| Animal health business | 1,952 | |||
| Overseas businesses | 908 | |||
| Other businesses | 38 |
(i) Pharmaceutical business
The pharmaceutical business, which focuses on the three fields of internal medicine, obstetrics and gynecology, and urology, remained in line with the previous fiscal year despite the impact of annual NHI drug price revisions. By product, sales of "RELUMINA," a treatment for uterine fibroids and endometriosis in the obstetrics and gynecology field, remained at the same level as the previous fiscal year, at ¥2,776 million (up 0.3% YoY). In comparison, sales of "DroEthi," a treatment for dysmenorrhea, came to ¥1,946 million (down 3.8% YoY). Sales of "THYRADIN," a thyroid hormone agent and mainstay product in the internal medicine field, grew steadily to ¥2,257 million (up 6.2% YoY), partly aided by a positive revision in drug prices, while "RIFXIMA," a poorly absorbed rifamycin-based antimicrobial agent, also performed well, reaching ¥1,982 million (up 4.2% YoY). In the urology field, sales of 'LEUPRORELIN,' an LH-RH derivative microcapsule sustained-release agent, amounted to ¥1,064 million (up 10.5% YoY).
As a result of the above, net sales were ¥14,484 million (down 0.2% YoY), remaining at the same level as the previous fiscal year. However, segment profit was ¥1,132 million (down 33.3% YoY) due to increases in cost of sales driven by rising raw material prices and other costs, as well as research and development expenses associated with the progress of clinical trials, among other factors.
(ii) Animal Health Business
In the animal health business, which sells veterinary pharmaceuticals, feed additives, and other products, net sales were ¥1,952 million (up 6.1% YoY), driven mainly by livestock pharmaceuticals and feed additives. However, segment profit was ¥44 million (down 65.4% YoY) due to an increase in procurement prices for feed additives caused by the weaker yen and geopolitical risks.
(iii) Overseas Business
At Ha Tay Pharmaceutical Joint Stock Company, a Vietnamese pharmaceutical company, net sales were ¥908 million (down 25.9% YoY) and a segment loss of ¥35 million was recorded (compared to a segment profit of ¥58 million in the same period of the previous fiscal year). This downturn was due to difficulties in procuring active pharmaceutical ingredients from the Middle East for its mainstay products.
(iv) Other Businesses
In the Other Businesses segment, which operates in areas such as clinical testing services and medical devices, net sales were ¥38 million (down 33.4% YoY), and a segment loss of ¥8 million was recorded (compared to a loss of ¥2 million in the same period of the previous fiscal year).
Financial Position
Overview of Financial Position Summary
-
Total assets
109,905 million yen
Change from end of previous fiscal year (2.2)%
-
Net assets
77,296 million yen
Change from end of previous fiscal year 0.6%
-
Equity ratio
64.4 %
Change from end of previous fiscal year 1.8point
Overview of Financial Position
(Assets)
Total assets at the end of the first quarter of the current consolidated fiscal year decreased by ¥2,474 million from the end of the previous consolidated fiscal year to ¥109,905 million. This was primarily due to a decrease in cash and deposits, other current assets, and other factors.
(Liabilities)
Total liabilities at the end of the first quarter of the current consolidated fiscal year decreased by ¥2,951 million from the end of the previous consolidated fiscal year to ¥32,608 million. This was primarily due to a decrease in other current liabilities, other provisions, and other factors.
(Net assets)
Total net assets at the end of the first quarter of the current consolidated fiscal year increased by ¥477 million from the end of the previous consolidated fiscal year to ¥77,296 million. This was primarily due to an increase in the valuation difference on available-for-sale securities.
The equity ratio increased by 1.8 percentage points from the end of the previous consolidated fiscal year to 64.4%.